Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
biospace

Windtree is Bringing Patients Back from Cardiogenic Shock in Phase II

New data unveiled by Windtree Therapeutics shows significant promise in heart failure patients who have deteriorated into cardiogenic shock.

CGT

TCR Search-and-Capture: Working Toward Personalized Cancer Therapy

Cell and gene therapy is not immune to the personalized medicine trend, and BlueSphere Bio hopes its leading T-cell receptor engineering (TCR) platform, along with its TCX-101 clinical candidate, can ultimately bolster the armamentarium for patients with hematologic malignancies and solid tumors.

biospace

AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology

BlueSphere Bio, for example, is trying to improve the efficacy of allogeneic stem cell transplant (alloSCT) treatments for patients with hematologic malignancies and solid tumors using its T-cell receptor (TCR) discovery platform. That platform, TCXpress™, identifies TCRs that may be especially efficacious against some of the most challenging types of cancer.

biospace

Aadi, SOTIO and Ikena Target Cancer-Causing Mutations at AACR  

SOTIO, a biotech company based in Prague and Cambridge, MA, focuses on improving CAR-T therapies and stable antibody-drug conjugates (ADCs). In its poster presentation, SOTIO announced preclinical data on its immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030. The company’s focus, however, was on its oral presentation featuring SOT101. 

BioProcessOnline

Commensal Viral Vectors With Ring Therapeutics’ Tuyen Ong, M.D.

Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering

Biosion grants Pyxis Oncology global rights to cancer drug in $232.5M deal

Biosion Inc. has out-licensed ex-China rights for its anti-Siglec-15 monoclonal antibody BSI-060T and additional preclinical assets with the same target to Pyxis Oncology Inc. for $10 million up front and potential milestone payments of up to $222.5 million, plus single to low double-digit royalties on commercial sales.

biospace

With Positive Phase II Results, Cerevance Proves Concept in Parkinson’s

Private drug discovery company Cerevance reported positive clinical trial results Thursday for CVN424, an experimental treatment for Parkinson’s disease. The drug was discovered using Cerevance’s NETSseq platform, which holds potential for Parkinson’s treatments as well as many other diseases caused by transcriptional genetic errors.

endpoints

Inside the race to make psychedelics ‘mainstream medicines’

When Berra Yazar-Klosinski was wrapping up her PhD in molecular cell and developmental biology at UC Santa Cruz, there was an unassuming little office right down the road, hidden inside a bungalow-style house with a postage-square lawn.